Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT04077736
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing, China
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT04077684
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04062006
Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT04062019
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Phase 1
Withdrawn
- Conditions
- Effect of DrugsPediatric CancerProgression
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Peking University People's Hospital
- Registration Number
- NCT04044378
- Locations
- 🇨🇳
Lu Xie, Beijing, Beijing, China
Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
Phase 2
- Conditions
- Effect of DrugsQuality of LifeChordomaAdvanced Cancer
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04042597
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS
Completed
- Conditions
- Osteosarcoma
- Interventions
- Other: cytology specimen
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT03997747
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
Assessment of Breast Cancer-Related Arm Lymphedema
- Conditions
- Breast Cancer
- Interventions
- Diagnostic Test: ICG lymphography、CM、VD、Bioelectrical impedance technology、self-reportDiagnostic Test: Bioelectrical impedance technology、CM
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 1600
- Registration Number
- NCT03978754
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Effects of Combination Therapy With Camouflage in the Repigmentation of Vitiligo
Phase 1
Completed
- Conditions
- Vitiligo
- Interventions
- Combination Product: CapulinTMOther: topical applications and NB-UVB
- First Posted Date
- 2019-06-04
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03973073
- Locations
- 🇨🇳
Peking university people's hospital, Beijing, Beijing, China
Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution
Phase 3
Active, not recruiting
- Conditions
- Stem Cell Transplant Complications
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 130
- Registration Number
- NCT03967665
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath